Biosimilars Sponsors Seek Changes In US FDA Guidance On Comparative Analytical Assessments
Executive Summary
Companies generally support decision not to require statistical equivalence testing but challenge agency’s skepticism about combining data from US and foreign reference products to set analytical similarity acceptance criteria.